tetano
Editor, Senior Moderator
Biomacromolecules
. 2024 Jun 6.
doi: 10.1021/acs.biomac.4c00365. Online ahead of print. Constructing a Ready-to-Use mRNA Vaccine Delivery System for the Prevention of Influenza A virus, Utilizing FDA-Approved Raw Materials
Yuyan Zhang[SUP] 1 2 [/SUP], Xinyu Zhuang[SUP] 3 [/SUP], Yingying Hu[SUP] 1 2 [/SUP], Jie Chen[SUP] 1 2 [/SUP], Kai Hao[SUP] 4 [/SUP], Zhaohui Tang[SUP] 1 2 [/SUP], Mingyao Tian[SUP] 3 [/SUP], Huayu Tian[SUP] 1 2 4 5 [/SUP], Ningyi Jin[SUP] 3 [/SUP], Xuesi Chen[SUP] 1 2 [/SUP]
Affiliations
Messenger ribonucleic acid (mRNA) vaccines, serving as a rapid and easily scalable emergency preventive measure, have played a pivotal role in preventing infectious diseases. The effectiveness of mRNA vaccines heavily relies on the delivery carrier, but the current market options are predominantly lipid nanoparticles. Their intricate preparation process and high transportation costs pose challenges for widespread use in remote areas. In this study, we harnessed FDA-approved polymer PLGA and lipid components widely employed in clinical experiments to craft a ready-to-use mRNA vaccine delivery system known as lipid-polymer hybrid nanoparticles (LPP). Following formulation optimization, the PDCD nanoparticles emerged as the most effective, showcasing exceptional mRNA delivery capabilities both in vitro and in vivo. Loading PDCD nanoparticles with mRNA encoding the H1N1 influenza virus HA antigen-fused M2e peptide enabled the successful induction of M2e-specific antibodies and T cell immune responses in immunized mice. After three rounds of vaccine immunization, the mice demonstrated weight recovery to normal levels and maintained a survival rate exceeding 80% following an encounter with the H1N1 influenza virus. The innovative mRNA delivery system that we designed demonstrates outstanding effectiveness in preventing infectious diseases, with the potential to play an even more significant role in future clinical applications.
. 2024 Jun 6.
doi: 10.1021/acs.biomac.4c00365. Online ahead of print. Constructing a Ready-to-Use mRNA Vaccine Delivery System for the Prevention of Influenza A virus, Utilizing FDA-Approved Raw Materials
Yuyan Zhang[SUP] 1 2 [/SUP], Xinyu Zhuang[SUP] 3 [/SUP], Yingying Hu[SUP] 1 2 [/SUP], Jie Chen[SUP] 1 2 [/SUP], Kai Hao[SUP] 4 [/SUP], Zhaohui Tang[SUP] 1 2 [/SUP], Mingyao Tian[SUP] 3 [/SUP], Huayu Tian[SUP] 1 2 4 5 [/SUP], Ningyi Jin[SUP] 3 [/SUP], Xuesi Chen[SUP] 1 2 [/SUP]
Affiliations
- PMID: 38843459
- DOI: 10.1021/acs.biomac.4c00365
Messenger ribonucleic acid (mRNA) vaccines, serving as a rapid and easily scalable emergency preventive measure, have played a pivotal role in preventing infectious diseases. The effectiveness of mRNA vaccines heavily relies on the delivery carrier, but the current market options are predominantly lipid nanoparticles. Their intricate preparation process and high transportation costs pose challenges for widespread use in remote areas. In this study, we harnessed FDA-approved polymer PLGA and lipid components widely employed in clinical experiments to craft a ready-to-use mRNA vaccine delivery system known as lipid-polymer hybrid nanoparticles (LPP). Following formulation optimization, the PDCD nanoparticles emerged as the most effective, showcasing exceptional mRNA delivery capabilities both in vitro and in vivo. Loading PDCD nanoparticles with mRNA encoding the H1N1 influenza virus HA antigen-fused M2e peptide enabled the successful induction of M2e-specific antibodies and T cell immune responses in immunized mice. After three rounds of vaccine immunization, the mice demonstrated weight recovery to normal levels and maintained a survival rate exceeding 80% following an encounter with the H1N1 influenza virus. The innovative mRNA delivery system that we designed demonstrates outstanding effectiveness in preventing infectious diseases, with the potential to play an even more significant role in future clinical applications.